According to FutureWise analysis the market for Carfilzomib in 2023 wasUS$ 0.2 billion, and is expected to reach US$ 0.25 billion by 2031 at a CAGR of 2.80%. Carfilzomib (also known as Kyprolis) is an anti-cancer medication that is derived from epoxomicin. This is a naturally occurring compound. Carfilzomib is a drug that binds to the 20-S proteasome. It also inhibits chymotrypsin activity....